RESUMO
Crohn's disease is a debilitating, Chronic inflammatory disease that is neither medically or surgically Curable. [1] Approximately 60-70 percent of all patients with Crohn's disease will eventually need to undergo surgery for the disease. [2] In 20:40 percent of patients, the disease is complicated by the development of a Fistula or a deep penetrating abscess. [3] Several studies with INFLIXIMAB have clinically demonstrated that the antitumour necrosis factor-alpha therapy rapidly reduces signs and symptoms in patients with moderate to-severe Crohn's disease. [4] The objective: To increase awareness by this uncommon disease process and through light on a newly therapeutic agent that can reduce and maintain remission in a patient population in this retrospective study, we analyze the clinical records of 17 patients [13 males, 4 Females] as regard presentation, history, Clinical examination, investigation and treatment regimens and operative details. Four patients presented as acute appendicitis, 2 patients with terminal ileal perferation, 2 patients with abdominal masses, 3 patients with acute abdowen, 2 patients with peria pendicular abscess, 2 patients with intestiol abslructionand 2 cases with malnutrition. In 4 cases inflexemab was added to the treatment regimm leading to rapid cure Crohn's disease, though considered uncommon, can account for 10:60 percent afacute abdominal disorders. Thus every physician or surgeon in deal with acute abomen should bear in mind a Crohn's possibility Infliximab, a therapeutic agent that can induce and maintain remission, while promoting the restoration of intestinal mucosa, would prove to be most beneficial in such a patient population